0001209191-23-046090.txt : 20230816
0001209191-23-046090.hdr.sgml : 20230816
20230816180333
ACCESSION NUMBER: 0001209191-23-046090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230816
DATE AS OF CHANGE: 20230816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peng Katie
CENTRAL INDEX KEY: 0001983850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 231179331
MAIL ADDRESS:
STREET 1: C/O ADICET BIO, INC.
STREET 2: 200 BERKELEY STREET, 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-14
0
0001720580
Adicet Bio, Inc.
ACET
0001983850
Peng Katie
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
1
0
0
0
0
Stock Option (Right to Buy)
3.38
2023-08-14
4
D
0
70200
0.00
D
2033-07-09
Common Stock
70200
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
70200
0.00
A
2033-07-09
Common Stock
70200
70200
D
On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
/s/ Nick Harvey, Attorney-in-Fact
2023-08-16